Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: FDA Delays Elagolix, Mylan Eyes For Neulasta Biosimilar Approval, And Duvelisib Gets Priority Review

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

Advertisement

Related Content

Pacira Sees Big Opportunity In Exparel's Narrow Nerve Block Indication
Pacira's Exparel Adds Nerve Block Indication For Shoulder Surgery In US
Keeping Track: Delay (For Celgene), Delay (For Allergan), Goose! (Approval For Lilly)
AbbVie's Got A Competitive Edge With Elagolix For Women With Uterine Fibroids
Keeping Track: DMD, RMAT, HIV, BTDs, Tc-99m – FTW
Neulasta Is 4-0 Versus Biosimilars Now That Mylan Has A CRL From FDA
Verastem Sees Phase III Success With PIK3 Inhibitor Dropped By AbbVie
Taking Biosimilars Down A PEG: Why Copying Neulasta Isn’t So Easy
Infinity Doesn't Sugarcoat Disappointing Duvelisib Data
Another Elagolix Study Supports AbbVie's NDA, But Which Dose?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122899

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel